St. Jude Medical (NYSE:STJ) had declared a cash dividend of $0.3100 on Aug 3, 2016. The shares will quote ex-dividend on Sep 28, 2016 and the record date has been fixed for Sep 30, 2016. On Aug 3, 2016 share price, the yield comes out to be 1.4845%. The dividend payable date has been fixed on Oct 28, 2016.
In a different note, On Jul 15, 2016, Wedbush said it Downgrades its rating on St. Jude Medical. In the research note, the firm Raises the price-target to $70.00 per share. The shares have been rated ‘Neutral’ by the firm. On Jul 11, 2016, Leerink Swann said it Downgrades its rating on St. Jude Medical. The shares have been rated ‘Market Perform’ by the firm. On May 11, 2016, Barclays said it Downgrades its rating on St. Jude Medical. In the research note, the firm Raises the price-target to $74.00 per share. The shares have been rated ‘Equal-weight’ by the firm. On May 10, 2016, SunTrust Robinson Humphrey said it Downgrades its rating on St. Jude Medical. The shares have been rated ‘Neutral’ by the firm.
St. Jude Medical (STJ) shares turned negative on Fridays trading session with the shares closing down -0.03 points or -0.04% at a volume of 14,20,454. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $83.69. The peak price level was also seen at $83.69 while the days lowest was $83.18. Finally the shares closed at $83.64. The 52-week high of the shares is $84 while the 52-week low is $48.83. According to the latest information available, the market cap of the company is $23,831 M.
St. Jude Medical(STJ) last announced its earnings results on Jul 20, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $1.56B. Analysts had an estimated revenue of $1.55B. Earnings per share were $1.06. Analysts had estimated an EPS of $1.06.
Several Insider Transactions has been reported to the SEC. On Feb 9, 2016, Jeff Fecho (VP, Global Quality) sold 10,408 shares at $51.71 per share price.Also, On Dec 22, 2015, John C Heinmiller (Executive Vice President) sold 8,009 shares at $61.16 per share price.On Dec 22, 2015, Jeff Dallager (VP and Corporate Controller) sold 501 shares at $60.94 per share price, according to the Form-4 filing with the securities and exchange commission.
St. Jude Medical Inc. develops manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management cardiovascular and atrial fibrillation therapy areas and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems bradycardia pacemaker systems atrial fibrillation (AF) products (electrophysiology introducers and catheters advanced cardiac mapping navigation and recording systems and ablation systems) vascular products (vascular closure products pressure measurement guidewires optical coherence tomography (OCT) imaging products heart failure monitoring device and other vascular accessories) structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).